Assuntos
Neoplasias Mamárias Experimentais/tratamento farmacológico , Mercaptopurina/uso terapêutico , Nucleosídeos/uso terapêutico , Sarcoma 180/tratamento farmacológico , Anormalidades Induzidas por Medicamentos , Animais , Azasserina/uso terapêutico , Carcinoma de Ehrlich/metabolismo , DNA de Neoplasias/biossíntese , Feminino , Glucosiltransferases/análise , Leucemia L1210/tratamento farmacológico , Mercaptopurina/toxicidade , Camundongos , Nucleosídeos/toxicidade , Oxirredutases/metabolismo , Fosfotransferases/análise , Gravidez , Prenhez , Sarcoma Experimental/tratamento farmacológicoRESUMO
It has been demonstrated in animal studies that, in animals heterozygous for pericentric chromosomal inversions, loop formation is greatly reduced during meiosis. This results in absence of recombination within the inverted segment, with recombination seen only outside the inversion. A recent study in yeast has shown that telomeres, rather than centromeres, lead in chromosome movement just prior to meiosis and may be involved in promoting recombination. We studied by cytogenetic analysis and DNA polymorphisms the nature of meiotic recombination in a three-generation family with a large pericentric X chromosome inversion, inv(X)(p21.1q26), in which Duchenne muscular dystrophy (DMD) was cosegregating with the inversion. On DNA analysis there was no evidence of meiotic recombination between the inverted and normal X chromosomes in the inverted segment. Recombination was seen at the telomeric regions, Xp22 and Xq27-28. No deletion or point mutation was found on analysis of the DMD gene. On the basis of the FISH results, we believe that the X inversion is the mutation responsible for DMD in this family. Our results indicate that (1) pericentric X chromosome inversions result in reduction of recombination between the normal and inverted X chromosomes; (2) meiotic X chromosome pairing in these individuals is likely initiated at the telomeres; and (3) in this family DMD is caused by the pericentric inversion.
Assuntos
Inversão Cromossômica , Distrofias Musculares/genética , Recombinação Genética , Cromossomo X , DNA/sangue , Feminino , Triagem de Portadores Genéticos , Ligação Genética , Marcadores Genéticos , Humanos , Hibridização in Situ Fluorescente , Cariotipagem , Escore Lod , Linfócitos , Masculino , Linhagem , Reação em Cadeia da Polimerase , Polimorfismo Genético , Sequências Repetitivas de Ácido NucleicoRESUMO
We report a child with clinical findings consistent with Werdnig-Hoffmann disease (spinal muscular atrophy type I) who was found not to have the homozygous absence of the survival motor neurone (SMN(T)) gene observed in approximately 95% of spinal muscular atrophy patients. A quantitative PCR based dosage assay for SMN(T) copy number showed that this patient possessed a single copy of the SMN(T) gene. Heteroduplex and sequence analysis of the remaining copy of SMN(T) showed a 2 base pair deletion within exon 4 which produces a frameshift and premature termination of the deduced SMN(T) protein. This protocol of initial SMN(T) gene dosage analysis followed by mutation detection allows identification of SMA compound heterozygotes (patients lacking one copy of SMN(T) and having another mutation in their other copy), thereby increasing the sensitivity of SMA molecular diagnosis.